Skip to main content
logo
Duality Biotherapeutics, Inc. (HKG:9606)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
201.80
+0.20 (0.10%)
Sep 30, 2026, 4:08 PM HKT

Duality Biotherapeutics Financials Overview

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023
Period EndingJun '26 Dec '25 Dec '24 Dec '23
Revenue
842.131,8521,9411,787
Revenue Growth
-54.52%-4.61%8.66%-
Gross Profit
-233.67589.09784.671,359
Operating Income
-1,494-460.12-187.04736.27
Net Income
-1,439-2,595-1,050-357.51
Earnings Per Share
-16.09-39.82-131.30-44.69
EPS Growth
----

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023
Period EndingJun '26 Dec '25 Dec '24 Dec '23
Cash & Investments
3,0433,3801,3971,136
Total Debt
379.46149.785.295.32
Net Cash (Debt)
2,6633,2301,3921,131
Net Cash Growth
-17.56%132.13%23.07%-
Net Cash Per Share
29.7849.58173.96141.35

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023
Period EndingJun '26 Dec '25 Dec '24 Dec '23
Operating Cash Flow
-818.88194.58285.78816.34
Capital Expenditures
-14.34-11.5-4.08-11.28
Free Cash Flow
-833.23183.08281.7805.05
Free Cash Flow Growth
--35.01%-65.01%-

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023
Period EndingJun '26 Dec '25 Dec '24 Dec '23
Gross Margin
-27.75%31.81%40.42%76.06%
Operating Margin
-177.37%-24.85%-9.63%41.21%
Pretax Margin
-170.82%-140.13%-52.26%-11.32%
Profit Margin
-170.82%-140.13%-54.11%-20.01%
FCF Margin
-98.94%9.89%14.51%45.06%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023
Period EndingSep '26 Dec '25 Dec '24 Dec '23
P/FCF Ratio
-130.88--
PS Ratio
18.7912.94--